Literature DB >> 28287550

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.

Sylvia F Boj1, Annelotte M Vonk2, Marvin Statia1, Jinyi Su1, Robert R G Vries1, Jeffrey M Beekman3, Hans Clevers4.   

Abstract

Recently-developed cystic fibrosis transmembrane conductance regulator (CFTR)-modulating drugs correct surface expression and/or function of the mutant CFTR channel in subjects with cystic fibrosis (CF). Identification of subjects that may benefit from these drugs is challenging because of the extensive heterogeneity of CFTR mutations, as well as other unknown factors that contribute to individual drug efficacy. Here, we describe a simple and relatively rapid assay for measuring individual CFTR function and response to CFTR modulators in vitro. Three dimensional (3D) epithelial organoids are grown from rectal biopsies in standard organoid medium. Once established, the organoids can be bio-banked for future analysis. For the assay, 30-80 organoids are seeded in 96-well plates in basement membrane matrix and are then exposed to drugs. One day later, the organoids are stained with calcein green, and forskolin-induced swelling is monitored by confocal live cell microscopy at 37 °C. Forskolin-induced swelling is fully CFTR-dependent and is sufficiently sensitive and precise to allow for discrimination between the drug responses of individuals with different and even identical CFTR mutations. In vitro swell responses correlate with the clinical response to therapy. This assay provides a cost-effective approach for the identification of drug-responsive individuals, independent of their CFTR mutations. It may also be instrumental in the development of future CFTR modulators.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28287550      PMCID: PMC5408767          DOI: 10.3791/55159

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  33 in total

Review 1.  Progress in therapies for cystic fibrosis.

Authors:  Kris De Boeck; Margarida D Amaral
Journal:  Lancet Respir Med       Date:  2016-04-01       Impact factor: 30.700

2.  Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.

Authors:  Johanna F Dekkers; Ricardo A Gogorza Gondra; Evelien Kruisselbrink; Annelotte M Vonk; Hettie M Janssens; Karin M de Winter-de Groot; Cornelis K van der Ent; Jeffrey M Beekman
Journal:  Eur Respir J       Date:  2016-04-21       Impact factor: 16.671

Review 3.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

4.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

5.  Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

Authors:  D D Zomer-van Ommen; L A W Vijftigschild; E Kruisselbrink; A M Vonk; J F Dekkers; H M Janssens; K M de Winter-de Groot; C K van der Ent; J M Beekman
Journal:  J Cyst Fibros       Date:  2015-08-05       Impact factor: 5.482

6.  Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells.

Authors:  Henner F Farin; Johan H Van Es; Hans Clevers
Journal:  Gastroenterology       Date:  2012-08-23       Impact factor: 22.682

7.  Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.

Authors:  Johanna F Dekkers; Gitte Berkers; Evelien Kruisselbrink; Annelotte Vonk; Hugo R de Jonge; Hettie M Janssens; Inez Bronsveld; Eduard A van de Graaf; Edward E S Nieuwenhuis; Roderick H J Houwen; Frank P Vleggaar; Johanna C Escher; Yolanda B de Rijke; Christof J Majoor; Harry G M Heijerman; Karin M de Winter-de Groot; Hans Clevers; Cornelis K van der Ent; Jeffrey M Beekman
Journal:  Sci Transl Med       Date:  2016-06-22       Impact factor: 17.956

8.  Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium.

Authors:  D N Sheppard; M R Carson; L S Ostedgaard; G M Denning; M J Welsh
Journal:  Am J Physiol       Date:  1994-04

9.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Authors:  Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman
Journal:  Lancet Respir Med       Date:  2014-06-24       Impact factor: 30.700

Review 10.  Modeling Development and Disease with Organoids.

Authors:  Hans Clevers
Journal:  Cell       Date:  2016-06-16       Impact factor: 41.582

View more
  24 in total

1.  Genetic Engineering of Primary Mouse Intestinal Organoids Using Magnetic Nanoparticle Transduction Viral Vectors for Frozen Sectioning.

Authors:  Lingling Xian; Lionel Chia; Dan Georgess; Li Luo; Shuai Shuai; Andrew J Ewald; Linda M S Resar
Journal:  J Vis Exp       Date:  2019-05-10       Impact factor: 1.355

2.  Fully synthetic matrices for in vitro culture of primary human intestinal enteroids and endometrial organoids.

Authors:  Victor Hernandez-Gordillo; Timothy Kassis; Arinola Lampejo; GiHun Choi; Mario E Gamboa; Juan S Gnecco; Alexander Brown; David T Breault; Rebecca Carrier; Linda G Griffith
Journal:  Biomaterials       Date:  2020-05-25       Impact factor: 12.479

3.  In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.

Authors:  Xingshen Sun; Yaling Yi; Ziying Yan; Bradley H Rosen; Bo Liang; Michael C Winter; T Idil Apak Evans; Pavana G Rotti; Yu Yang; Jaimie S Gray; Soo Yeun Park; Weihong Zhou; Yulong Zhang; Shashanna R Moll; Lisa Woody; Dao M Tran; Licong Jiang; Annelotte M Vonk; Jeffrey M Beekman; Paul Negulescu; Fred Van Goor; Dennis F Fiorino; Katherine N Gibson-Corley; John F Engelhardt
Journal:  Sci Transl Med       Date:  2019-03-27       Impact factor: 17.956

4.  Anion Transport Across Human Gallbladder Organoids and Monolayers.

Authors:  Keyan Zarei; Ian M Thornell; David A Stoltz
Journal:  Front Physiol       Date:  2022-05-24       Impact factor: 4.755

Review 5.  Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics.

Authors:  Deborah M Cholon; Martina Gentzsch
Journal:  Curr Opin Pharmacol       Date:  2022-04-21       Impact factor: 4.768

Review 6.  CFTR modulator theratyping: Current status, gaps and future directions.

Authors:  John Paul Clancy; Calvin U Cotton; Scott H Donaldson; George M Solomon; Donald R VanDevanter; Michael P Boyle; Martina Gentzsch; Jerry A Nick; Beate Illek; John C Wallenburg; Eric J Sorscher; Margarida D Amaral; Jeffrey M Beekman; Anjaparavanda P Naren; Robert J Bridges; Philip J Thomas; Garry Cutting; Steven Rowe; Anthony G Durmowicz; Martin Mense; Kris D Boeck; William Skach; Christopher Penland; Elizabeth Joseloff; Hermann Bihler; John Mahoney; Drucy Borowitz; Katherine L Tuggle
Journal:  J Cyst Fibros       Date:  2018-06-20       Impact factor: 5.482

7.  Establishment of Pancreatic Organoids from Normal Tissue and Tumors.

Authors:  Else Driehuis; Ana Gracanin; Robert Gerhardus Jacob Vries; Hans Clevers; Sylvia Fernández Boj
Journal:  STAR Protoc       Date:  2020-12-04

Review 8.  Disease Modeling Using 3D Organoids Derived from Human Induced Pluripotent Stem Cells.

Authors:  Beatrice Xuan Ho; Nicole Min Qian Pek; Boon-Seng Soh
Journal:  Int J Mol Sci       Date:  2018-03-21       Impact factor: 5.923

9.  Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.

Authors:  Venkateshwar Mutyam; Jyoti Sharma; Yao Li; Ning Peng; Jianguo Chen; Li Ping Tang; Emily Falk Libby; Ashvani K Singh; Katja Conrath; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

10.  Health Characteristics of Patients with Cystic Fibrosis whose Genotype Includes a Variant of the Nucleotide Sequence c.3140-16T>A and Functional Analysis of this Variant.

Authors:  Elena Kondratyeva; Tatyana Bukharova; Anna Efremova; Yuliya Melyanovskaya; Natalia Bulatenko; Ksenia Davydenko; Alexandra Filatova; Mikhail Skoblov; Stanislav Krasovsky; Nika Petrova; Alexander Polyakov; Tagui Adyan; Elena Amelina; Vera Shadrina; Elena Zhekaite; Aysa Zodbinova; Alexander Chernyak; Rena Zinchenko; Sergei Kutsev; Dmitry Goldshtein
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.